Barclays’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Barclays’s Portfolio VAXX Stock Details VAXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2	Closed	–	–	5589
2024 Q2	$0	Sell	2 -29,833	-100%	-$11.1K	﹤0.01%	5420
2024 Q1	$21.4K	Sell	29,835 -28,657	-49%	-$20.8K	﹤0.01%	4748
2023 Q4	$49.7K	Buy	58,492 +50,698	+650%	+$49K	﹤0.01%	4776
2023 Q3	$10.7K	Sell	7,794 -837	-10%	-$1.81K	﹤0.01%	4291
2023 Q2	$21.8K	Buy	+8,631	New	+$18.3K	﹤0.01%	4120

Barclays's VAXX Position: Q3 2024 in Review

Barclays sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q3 2024, closing a stake of 2 shares.

Barclays first reported a position in VAXX in Q2 2023 and held it in 5 quarters. The position peaked at $49.7K in Q4 2023. 0 funds tracked by Wall St. Rank hold VAXX as of Q3 2024.

Barclays reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q3 2024 after selling out during the quarter.
Barclays sold 2 Vaxxinity, Inc. Class A Common Stock shares in Q3 2024.
Barclays first reported a position in Vaxxinity, Inc. Class A Common Stock in Q2 2023 and held it in 5 quarters.
Barclays's Vaxxinity, Inc. Class A Common Stock position peaked at $49.7K in Q4 2023.
0 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.